NASDAQ:SABS SAB Biotherapeutics Q1 2024 Earnings Report $1.73 -0.02 (-1.14%) As of 07/3/2025 02:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast SAB Biotherapeutics EPS ResultsActual EPS-$0.54Consensus EPS -$0.98Beat/MissBeat by +$0.44One Year Ago EPSN/ASAB Biotherapeutics Revenue ResultsActual Revenue$0.95 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASAB Biotherapeutics Announcement DetailsQuarterQ1 2024Date5/20/2024TimeN/AConference Call DateMonday, May 20, 2024Conference Call Time7:00AM ETUpcoming EarningsSAB Biotherapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Friday, August 8, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) SAB Biotherapeutics Earnings HeadlinesSABS - SAB Biotherapeutics Inc Chart - MorningstarJuly 4 at 7:57 PM | morningstar.comMSAB Biotherapeutics, Inc.: SAB BIO Announces Q1 2025 Financial Results and Provides Company UpdatesMay 9, 2025 | finanznachrichten.deBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change. July 5 at 2:00 AM | Crypto 101 Media (Ad)SAB BIO Announces Q1 2025 Financial Results and Provides Company UpdatesMay 9, 2025 | globenewswire.comCraig-Hallum Reaffirms Their Buy Rating on SAB Biotherapeutics (SABS)April 3, 2025 | markets.businessinsider.comSAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2024 Operating and Financial ResultsApril 2, 2025 | finanznachrichten.deSee More SAB Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SAB Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SAB Biotherapeutics and other key companies, straight to your email. Email Address About SAB BiotherapeuticsSAB Biotherapeutics (NASDAQ:SABS), a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.View SAB Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
